ADSS2

Across TCGA pan-cancer cohorts, ADSS2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ADSS2’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where ADSS2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ADSS2 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

PDAC, LSCC, and LUAD are the cancer types where ADSS2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ADSS2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Male	All	+0.653	<.001	11	view →
LSCC	Male	II,III,IV	+0.632	<.001	9	view →
LUAD	Male	All	+0.371	<.001	9	view →
HNSC	Male	III,IV	+0.466	<.001	8	view →
CCRCC	Male	II,III,IV	−0.150	<.001	7	view →
OV	All	All	+0.481	<.001	2	view →
COAD	All	IV	+0.291	.016	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ADSS2–PDAC

Open the PDAC breakdown →